132.82
前日終値:
$130.88
開ける:
$131.91
24時間の取引高:
9.80M
Relative Volume:
1.45
時価総額:
$223.47B
収益:
$42.34B
当期純損益:
$13.50B
株価収益率:
17.23
EPS:
7.71
ネットキャッシュフロー:
$6.66B
1週間 パフォーマンス:
+3.08%
1か月 パフォーマンス:
+0.67%
6か月 パフォーマンス:
+11.99%
1年 パフォーマンス:
+25.40%
Abbott Laboratories Stock (ABT) Company Profile
名前
Abbott Laboratories
セクター
電話
(224) 667-6100
住所
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
ABT を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
ABT
Abbott Laboratories
|
132.82 | 223.47B | 42.34B | 13.50B | 6.66B | 7.71 |
![]()
BSX
Boston Scientific Corp
|
104.93 | 150.72B | 17.55B | 2.03B | 2.37B | 1.37 |
![]()
SYK
Stryker Corp
|
378.22 | 139.34B | 22.60B | 2.99B | 3.49B | 7.76 |
![]()
MDT
Medtronic Plc
|
84.85 | 107.15B | 33.20B | 4.26B | 5.47B | 3.29 |
![]()
EW
Edwards Lifesciences Corp
|
75.65 | 44.54B | 5.54B | 4.18B | 259.90M | 7.00 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2024-10-08 | 開始されました | Oppenheimer | Outperform |
2024-09-19 | 開始されました | Piper Sandler | Overweight |
2024-07-30 | ダウングレード | Edward Jones | Buy → Hold |
2024-05-30 | 開始されました | Goldman | Buy |
2023-07-21 | アップグレード | Wolfe Research | Underperform → Peer Perform |
2023-05-30 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
2023-04-20 | 繰り返されました | Barclays | Overweight |
2023-04-20 | 繰り返されました | Bernstein | Outperform |
2023-04-20 | 繰り返されました | JP Morgan | Overweight |
2023-04-20 | 繰り返されました | Raymond James | Outperform |
2023-04-20 | 繰り返されました | UBS | Buy |
2023-04-20 | 繰り返されました | Wolfe Research | Underperform |
2023-03-29 | 開始されました | UBS | Buy |
2022-10-26 | 開始されました | Mizuho | Neutral |
2022-10-18 | 開始されました | Barclays | Overweight |
2022-10-12 | 開始されました | Jefferies | Hold |
2022-07-06 | 開始されました | Wolfe Research | Underperform |
2022-03-02 | 再開されました | BofA Securities | Buy |
2022-01-27 | 繰り返されました | Credit Suisse | Outperform |
2022-01-27 | 繰り返されました | Morgan Stanley | Overweight |
2022-01-27 | 繰り返されました | Raymond James | Outperform |
2022-01-27 | 繰り返されました | UBS | Buy |
2021-12-10 | 開始されました | RBC Capital Mkts | Outperform |
2021-10-27 | アップグレード | Atlantic Equities | Neutral → Overweight |
2021-10-14 | 開始されました | Redburn | Neutral |
2021-05-25 | 開始されました | Barclays | Overweight |
2021-04-15 | 開始されました | Atlantic Equities | Neutral |
2021-01-28 | アップグレード | BTIG Research | Neutral → Buy |
2020-09-11 | 開始されました | Wolfe Research | Outperform |
2020-06-01 | ダウングレード | Goldman | Neutral → Sell |
2020-03-05 | 開始されました | Citigroup | Buy |
2020-02-13 | 開始されました | Goldman | Neutral |
2020-02-06 | 再開されました | BTIG Research | Neutral |
2020-01-02 | ダウングレード | Guggenheim | Buy → Neutral |
2019-06-13 | 繰り返されました | BofA/Merrill | Buy |
2019-02-07 | 繰り返されました | BofA/Merrill | Buy |
2019-01-02 | ダウングレード | Citigroup | Neutral → Sell |
2018-11-30 | アップグレード | Goldman | Neutral → Buy |
2018-10-16 | 開始されました | Barclays | Overweight |
2018-06-27 | 開始されました | Bernstein | Outperform |
2018-01-30 | 繰り返されました | Citigroup | Neutral |
2018-01-25 | 繰り返されました | Stifel | Buy |
2018-01-25 | アップグレード | William Blair | Mkt Perform → Outperform |
2018-01-03 | 開始されました | Evercore ISI | Outperform |
2018-01-02 | アップグレード | JP Morgan | Neutral → Overweight |
2018-01-02 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
2017-10-19 | 繰り返されました | RBC Capital Mkts | Outperform |
2017-10-19 | 繰り返されました | Stifel | Buy |
すべてを表示
Abbott Laboratories (ABT) 最新ニュース
Abbott (ABT) Launches Rapid Concussion Test with MotoAmerica - GuruFocus
2 Stocks, 2 Decades, $200. Is This the Long-Term Dividend Play for Your Portfolio? - The Motley Fool
Abbott Laboratories Director Makes Significant Stock Sale! - TipRanks
Abbott Beats Bellwether In Formula MDL Ahead Of Trial - Law360
US judge allows testimony that Abbott and Mead Johnson preterm baby formula caused deadly disease - Reuters
Abbott Laboratories (ABT) Sees Stock Rise Following Favorable Court Ruling - GuruFocus
Abbott gains after upcoming baby formula case thrown out (ABT:NYSE) - Seeking Alpha
Abbott Laboratories First Quarter 2025 Earnings: EPS Misses Expectations - simplywall.st
Stroke Management Market Is Booming Worldwide | Abbott - openPR.com
Investors in Abbott Laboratories (NYSE:ABT) have seen notable returns of 52% over the past five years - Yahoo Finance
Abbott Laboratories Announces Executive Vice President’s Retirement - TipRanks
MotoAmerica Becomes First Sports Organization to Use Abbott's Rapid Blood Test for Concussion Evaluation On-site at Races - Stock Titan
Abbott Laboratories (ABT): Among the Best Stocks to Buy During Recession - Yahoo Finance
Abbott Laboratories price tries to shake off negative pressureForecast today01-05-2025 - Economies.com
MotoAmerica: More On Abbott Blood Test for Rapid Concussion Evaluation On-Site - Roadracing World
Abbott Laboratories (ABT): Jim Cramer Calls It a ‘Tour de Force’ — Why He’s Still Amazed at This Stock - Yahoo Finance
Abbott Laboratories (ABT) Announces Results of Annual Shareholders Meeting - GuruFocus
Abbott (ABT) Integrates Libre CGM Data with Epic's Health Records - GuruFocus
Abbott signs deal with Epic for CGM data integration (ABT:NYSE) - Seeking Alpha
Abbott Integrates Libre CGM’s Data with Epic’s EHR System - Medical Product Outsourcing
Abbott (ABT) Teams Up with Epic for Advanced Health Data Integra - GuruFocus
Abbott integrates Libre CGM data into Epic EHR workflows - Drug Delivery Business
Abbott Partners With Epic to Transform Diabetes Care for 280M Patients | ABT Stock News - Stock Titan
Sevoflurane Market Overall Study Report 2025-2032 | Abbott Laboratories, Baxter, Piramal Pharma Solutions - openPR.com
A Look Into Abbott Laboratories Inc's Price Over Earnings - Benzinga
Abbott Laboratories (NYSE:ABT) Unveils Breakthrough Leadless Pacemaker Advances In New Clinical Trials - simplywall.st
Abbott (ABT) Unveils Promising Results from Leadless Pacemaker S - GuruFocus
The Zacks Analyst Blog Highlights Abbott Laboratories, Boston Scientific and Medtronic - Yahoo Finance
Drug Eluting Stents Market Overall Study Report 2025-2032 | - openPR.com
Abbott Laboratories (NYSE:ABT) Is Doing The Right Things To Multiply Its Share Price - Yahoo Finance
Abbott Laboratories Insiders Sold US$3.3m Of Shares Suggesting Hesitancy - simplywall.st
The health care sector is a mixed picture, but Abbott Labs is a buy. - Forbes
Abbott Stuns with Study Results in PFA Market: Is It Enough? - Medical Device and Diagnostic industry
Pesticides Market to Experience Rapid Growth Driven by Abbott - openPR.com
Abbott Laboratories Says Investigational Pacemaker Shows Safety, Performance - marketscreener.com
India Medical Nutrition Market Overall Study Report 2025-2032 | - openPR.com
Abbott has positive study results for Aveir CSP leadless pacemaker - MassDevice
Abbott Laboratories: Strategic Advancements and Market Positioning with Volt PFA Platform Drive Buy Rating - TipRanks
Abbott announces new data from its Volt CE Mark Study - TipRanks
Breakthrough Heart Technology: Abbott's Leadless Pacemaker Trial Success Launches Major Global Study - Stock Titan
New data supports Abbott Volt pulsed field ablation system - MassDevice
Abbott Laboratories Says New Clinical Study Data Showcase Long-Term, Sustained Benefits Of Abbott's Volt(TM) Pfa System For Patients With Afib - marketscreener.com
Abbott's Revolutionary AFib Treatment Achieves 83.5% Freedom from Arrhythmia in Landmark Study - Stock Titan
FDA says recall of Abbott HeartMate power unit is serious - MassDevice
FDA announces new recall of Abbott heart pump accessories over significant safety risks - Cardiovascular Business
Clinical Diagnostics Market: Trends, Growth, and Key Players - openPR.com
Medtronic seeks FDA nod for insulin pump (MDT:NYSE) - Seeking Alpha
EPD Growth in Emerging Market Supports Abbott Stock Amid Macro Woes - Yahoo Finance
June 6th Options Now Available For Abbott Laboratories (ABT) - Nasdaq
The Zacks Analyst Blog Highlights Coca-Cola, Abbott Laboratories, RTX, Investors Title and Armanino Foods of Distinction - Yahoo Finance
Top Analyst Reports for Coca-Cola, Abbott & RTX - Yahoo Finance
Abbott Laboratories (ABT) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):